BACKGROUND: Denosumab, a fully human monoclonal antibody against RANK ligand, increased bone mineral density (BMD) and reduced fracture risk vs placebo in a phase 3 trial in men with prostate cancer on androgen deprivation therapy (ADT). The present analysis of this study evaluated BMD changes after 36 months in responder subgroups and in individual patients for three key skeletal sites (lumbar spine (LS), femoral neck (FN) and total hip (TH)) and the distal radius. METHODS: Men with nonmetastatic prostate cancer receiving ADT were treated with subcutaneous denosumab 60 mg (n ¼ 734) or placebo (n ¼ 734) every 6 months for up to 36 months in a phase 3, randomized, double-blind study. Patients were instructed to take supplemental calcium and vitamin D. For this BMD responder analysis, the primary outcome measure was the percentage change in BMD from baseline to month 36 at the LS, FN and TH as measured by dual-energy X-ray absorptiometry. BMD at the distal 1/3 radius at 36 months was measured in a substudy of 309 patients. RESULTS: At 36 months, significantly more patients in the denosumab arm had increases of 43% BMD from baseline at each site studied compared with placebo (LS, 78 vs 17%; FN, 48 vs 13%; TH, 48 vs 6%; distal 1/3 radius, 40 vs 7% (Po0.0001 for all)). BMD loss at the LS, FN and TH occurred in 1% of denosumab-treated patients vs 42% of placebo patients, and BMD gain at all three sites occurred in 69% of denosumab patients vs 8% of placebo patients. Lower baseline BMD was associated with highermagnitude BMD responses to denosumab at the LS, FN and TH. CONCLUSIONS: In men with prostate cancer receiving ADT, significantly higher BMD response rates were observed with denosumab vs placebo. Patients with lower baseline T-scores benefited the most from denosumab treatment.
INTRODUCTION
Prostate cancer is the most common malignancy in European men with an annual incidence of 0.1% representing nearly one quarter of all cancer diagnoses in this population. 1 Following the adoption of PSA screening in 1987, the diagnosis of prostate cancer has markedly increased. 2 During 2000--2004, the mortality rate from prostate cancer in Europe was 14.3 per 100 000 men representing 65 000 deaths annually. 3 Androgen deprivation therapy (ADT), using gonadotropin-releasing hormone agonists or bilateral orchiectomy to prevent hormone-dependent growth and metastasis of tumor cells, remains a mainstay of treatment for locally advanced or relapsing prostate cancer. 4 A claims sample of US Medicare beneficiaries from 1993 to 2000 demonstrated an increase in the use of ADT from 1.8 to 2.9%. 5 Whether by chemical castration or bilateral orchiectomy, ADT can result in marked bone loss and increased fracture risk. 6, 7 The treatment-induced loss in bone mineral density (BMD) is progressive: up to 4.8% of lumbar spine (LS) BMD and 3.9% of femoral neck (FN) BMD is lost in the first year with an overall BMD loss reaching B7% after 2 years of gonadotropin-releasing hormone agonist therapy. 8, 9 Denosumab is a fully human monoclonal antibody against RANK ligand, a key activator of osteoclast formation, function and survival. Denosumab inhibits osteoclast function and bone resorption, 10 and is approved as a treatment to increase bone mass in men at high risk for fracture receiving ADT for nonmetastatic prostate cancer. 11 In this phase 3, randomized, double-blind study of men receiving ADT for nonmetastatic prostate cancer, denosumab was associated with a 62% reduction in vertebral fractures (adjusted P ¼ 0.0125) at 36 months, with a marked reduction in fractures evident within the first year. 12 The study's primary result demonstrated that, at 24 months, denosumab produced a BMD increase at the LS of 6.7% compared with placebo (Po0.001); significant differences were also observed at the total hip (TH), FN and distal 1/3 radius. 12 Herein, we report the results of a responder analysis from this trial comparing percentage change in BMD from baseline between denosumab and placebo across four skeletal sites including the proportion of responders and magnitude of response. This analysis therefore extends the results presented previously from this trial 12, 13 and presents an assessment of proportional responses to densosumab therapy by skeletal site and responses by baseline BMD T-score.
MATERIALS AND METHODS
This randomized, double-blind, placebo-controlled trial evaluated denosumab for treating bone loss in men undergoing ADT for nonmetastatic prostate cancer. Inclusion criteria stipulated that men aged X70 years, or o70 years with a history of osteoporotic fracture or a BMD T-score at the LS, TH or FN oÀ1.0, and who had histologically confirmed prostate cancer, were eligible. Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 and to have undergone either bilateral orchiectomy or have begun ADT with a gonadotropinreleasing hormone agonist with therapy expected to continue for at least 12 months. Men were excluded if they were receiving concurrent anti-neoplastic therapy or radiotherapy, had a PSA concentration greater than 5 ng ml À1 after being on ADT for more than 1 month or had a BMD T-score o-4.0 at LS, TH or FN. A more detailed description of eligibility criteria has been previously published. 13 Patients were randomized to denosumab or placebo groups in a double-blind fashion using an interactive voice response system. Stratification at baseline was by age group (o70 vs X70 years old) and duration of ADT (p6 vs 46 months), and patients were randomly assigned to receive placebo or denosumab 60 mg subcutaneously every 6 months for up to 36 months. All patients were instructed to take supplemental calcium, X1 g daily, and either X400 IU vitamin D daily ( 12 Within a substudy, 309 patients also underwent BMD measurements at the distal 1/3 radius.
While the LS is composed primarily of trabecular bone, the radius is substantially cortical bone.
14 BMD assessments by dual X-ray absorptiometry of the LS, hip (TH, FN and trochanter), distal 1/3 radius and total body were performed on GE Lunar (GE Healthcare, Chalfont St Giles, UK) or Hologic (Hologic, Bedford, MA, USA) bone densitometers at baseline and at months 1, 3, 6, 12, 24 and 36. Men with BMD losses of more than 7% over a 12-month period or with a T-score oÀ4.0 at the TH or LS were evaluated for alternative treatment options.
Statistical analysis All randomized patients with available baseline and at least one post-baseline measurement of BMD were included in the analysis.
BMD measures were analyzed employing an analysis of covariance model using last observation value carried forward imputation with treatment group, baseline BMD value, machine type (Lunar vs Hologic), the interaction of baseline BMD value and machine type, age group (o70 vs X70 years) and duration of ADT (p6 vs 46 months) as covariates. Based on X-ray absorptiometry scanner precision of 1%, the least significant change in BMD at the LS at the 95% confidence level of 3% was chosen as the minimally clinically significant value to define responders in accordance with accepted standards. 15 
RESULTS
The first patient was enrolled in April 2004 and the last patient completed the study in May 2008. Overall, patient demographics and disease characteristics at baseline were similar between the two groups (Table 1) as recently described. 13 About 62% of enrolled patients completed the 36-month study. Withdrawal of consent (18%) was the primary reason for discontinuation and most occurred when patients declined participation for an additional year in the study when it was extended from 24 to 36 months. Baseline demographic characteristics of the 309 patients enrolled in the distal 1/3 radius substudy were similar to those of patients enrolled in the full study.
BMD responses from individual patients at 36 months are plotted as waterfall plots in Figure 1 showing the magnitude of individual responses. For all sites, the magnitude of BMD gains for patients in the denosumab group was greater overall than for the placebo group. A significantly greater proportion of patients in the denosumab group had clinically meaningful BMD increases of 43% at all three key skeletal sites: LS (78 vs 17% placebo), FN (48 vs 13% placebo) and TH (48 vs 6% placebo), Po0.0001 for all; Figure 1 . Compared with placebo, significantly more patients in the denosumab group had BMD increases of any magnitude (X0% change): LS (92 vs 40%), FN (81 vs 32%) and TH (87 vs 26%); (Figure 1 ). In the placebo group, 42% had BMD loss (defined as o0% BMD change) at all three key sites compared with 1% of patients in the denosumab group. In the substudy of patients evaluated for change from baseline in BMD at the distal 1/3 radius, 40% of patients in the denosumab group had increases in BMD of 43%, compared with 7% of placebo patients (Po0.0001; Figure 1 ). About 76% of patients receiving denosumab in the radius substudy had BMD increases of any magnitude compared with 28% in the placebo group. BMD losses were experienced by a greater number of patients in the placebo group compared with the denosumab group (72 vs 24%). Similarly, BMD losses in the placebo group were greater in magnitude overall than losses experienced by patients receiving denosumab in the radius substudy.
We also examined the magnitude of BMD responses by different baseline strata. In the denosumab group, the magnitude of response was dependent on the degree of osteopenia at baseline. In general, patients with lower baseline T-scores had greater BMD responses at all three key sites (Figure 2a) . The association between low baseline T-score and BMD response was significant at the LS and TH. In the placebo group, baseline Tscores were not correlated with BMD responses (Figure 2b) .
Adverse events reported in this study have been described elsewhere. 12 Briefly, 87% of patients in each group experienced at least one adverse event; the most common events were arthralgia (12%), back pain (11%) and constipation (10%). Treatment-related adverse events were reported for 0.4% of patients in the denosumab group and 0.6% of patients in the placebo group.
No-treatment-related serious adverse event was reported for more than one patient in either group.
DISCUSSION
In this study of men undergoing ADT for nonmetastatic prostate cancer, denosumab significantly improved BMD at the LS, TH, FN and distal radius compared with placebo at 12, 24 and 36 months of treatment. The current responder analysis revealed that a substantially higher proportion of patients treated with denosumab experienced gains in BMD at various body sites tested as compared with patients treated with placebo. The proportion of patients receiving placebo who experienced losses in BMD was substantial and significantly higher compared with denosumab despite daily calcium and vitamin D supplementation in both study arms. Outside of the clinical trial setting, the usage of calcium and vitamin D supplementation in patients treated with ADT can be expected to be low, 16 thus the responses in the placebo arm of this study are likely reflective of a best-case outcome. This also indicates that, while necessary, these supplements alone were not sufficient to prevent bone loss for most men in this at-risk population.
In this study, 12 clinically significant BMD improvements obtained at 12 months were maintained over the 36-month course of the study. The 12-month changes in BMD were comparable to those seen in a separate study by Greenspan et al. 17 of men with nonmetastatic prostate cancer given weekly The BMD gains achieved by patients in this study were similar to those observed with the same denosumab regimen in other populations. In postmenopausal women with low BMD, treated with denosumab 60 mg every 6 months, comparable BMD improvements were reported after 24 months at the LS (7.0%), TH (4.5%) and FN (3.7%) relative to placebo. 18 Similarly, in a study of postmenopausal women receiving aromatase inhibitors for early-stage breast cancer, a 7.6% gain in BMD at the LS relative to placebo was achieved after 24 months of denosumab treatment. 19 These responses, which exceed the predefined least significant change of 3%, represent BMD gains that are likely to have impact on fracture outcomes. 20 Individual patient data (Figure 2 ) demonstrate that overall, placebo-treated patients had greater magnitudes of bone loss at the radius than at other skeletal sites with 75% of this group losing bone at this site. The distal 1/3 radius is a site that allows for identification of what changes occur in cortical bone. As cortical bone is a significant determinant of bone strength, and as with aging and bone loss the cortical compartment becomes more relevant (than the trabecular compartment) for strength, 21 it is important to understand the impact of therapies at this site. The denosumab group achieved a 6.9% increase in BMD at the distal 1/3 radius relative to placebo at 36 months with 74% of patients experiencing BMD gains. At 24 months, BMD gains at the radius were greater (5.5%) than those observed in studies of denosumab in postmenopausal women with osteopenia at 24 months (3.5%), 18 and comparable to gains seen in women with nonmetastatic breast cancer receiving aromatase inhibitors (6.1%). 19 Reversal of bone loss at the radius, composed of primarily cortical bone, has not previously been reported in patients with prostate cancer treated with bisphosphonates. In the Greenspan study, patients receiving oral alendronate had a BMD loss of 0.9% from baseline at the radius, while placebo patients lost twice as much. 17 The analysis of BMD response by baseline T-score suggests that an augmented treatment benefit may be obtained in patients with lower baseline BMD, that is, in those patients who would be expected to benefit most from interventional measures to reduce fracture risk.
To our knowledge, this represents the first such responder analysis for osteoclast inhibitors by skeletal site. In men receiving ADT, the risk of any fracture is increased 22 and BMD gains at key skeletal sites should translate into reduced fracture risk. 23 Hip BMD has been suggested to be of paramount importance for prediction of hip and nonvertebral fractures in men 24 while spine BMD alone may be more critical in predicting vertebral fractures in women. 25 In this study, denosumab produced robust improvements in BMD at all skeletal sites tested, including the distal 1/3 radius, whereas in the aforementioned Greenspan study patients receiving oral alendronate had a 0.9% loss of BMD from baseline at the radius. 17 While there is unequivocal data to show that BMD improvements lead to reductions in fractures, the identification of skeletal sites most predictive of individual fracture types is still open to debate.
In summary, for men undergoing ADT for nonmetastatic hormone-sensitive prostate cancer, a substantial proportion of patients experience bone loss despite calcium and vitamin D supplementation. Denosumab increased BMD at all measured sites compared with placebo. Moreover, for the overwhelming majority of men, denosumab not only prevented ADT-associated bone loss but improved bone density in a clinically meaningful way. Most importantly, as previously reported, these changes in BMD were reflected in the statistically significant reduction of vertebral fractures in men treated with denosumab.
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